GCIQ&A: hVIVO's CEO Mo Khan on developing the industry’s first commercial hMPV human challenge model
Vox speak to (HVO ) Mo Khan about the company’s latest human challenge model, to be developed in conjunction with a customer to develop the world’s first treatments for the Human metapneumovirus.
0:30 Discussing the brand-new human challenge model, the world’s first for the Human metapneumovirus (hMPV) to be developed in conjunction with a large US biotech.
1:51 The importance of developing treatments for hMPV, for which no vaccine or antiviral currently exists.
3:14 Why the customer has opted for a human challenge model to support its vaccine development.
4:11 Insights into the customer, a long-term partner of hVivo, and how hVivo will be using the model for other customers.
4:57 The timescales and process involved in bringing the hMPV human challengemodel into use.
6:08 Further validation of the power of human challenge models in expediting rapid drug development
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.